ArticleMicrobial biotechnology2025
Precise Engineering and Efficient Biosynthesis of Robust and High-Activity Human Haemoglobin for Artificial Oxygen Carriers.
Article in Microbial biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Recombinant human haemoglobin (rHb) is a tetramer protein with heme as cofactors, which have extensive applications in the fields of biomaterials and biomedical therapeutics. However, due to the poor structural stability, the dissociation of heme, weak oxygen transport efficiency, and lower activity, the utilisation of rHb is severely limited in artificial oxygen carriers. Herein, based on the novel developed high-throughput screening strategies and semi-rational design, the engineered rHb mutant with strong stability and heme-binding ability was obtained. In addition, through the homology alignment and rational design, the oxygen transport capacity of rHb was significantly enhanced. Furthermore, the bottlenecks of heme supply were overcome by applying the fine-tuned heme synthesis in Escherichia coli. Finally, the robust and high-activity rHb mutant was synthesised and can be used as a new generation of artificial oxygen carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.